c-myc and c-myb expression in acute myelogenous leukemia.
Monoclonal antibodies and flow cytometry were used to detect the expression of c-myc and c-myb in the bone marrow (BM) and peripheral blood (PB) cells of patients with acute myelogenous leukemia (AML). The expression of neither gene was correlated with the percent blast cells in the BM or PB nor was there a correlation between c-myc and c-myb expression. A wide range of expression of each gene was found within each FAB type of AML. Patients who had a high proportion of leukemia cells expressing c-myb were less likely to respond to remission induction therapy than patients in whom a low proportion of cells expressed c-myb. This association appears to reflect an inverse relationship between the proportion of cells expressing c-myb and the sensitivity of leukemia cells to the killing effects of chemotherapy in vivo. Treatment outcome was unrelated to c-myc expression.
Gopal
V
V
University of Cincinnati Medical Center, Ohio 45267-0508.
Hulette
B
B
Li
Y Q
YQ
Kuvelkar
R
R
Raza
A
A
Larson
R
R
Goldberg
J
J
Tricot
G
G
Bennett
J
J
Preisler
H
H
D001853:Bone Marrow / Q000648:ultrastructure; D005434:Flow Cytometry; D015870:Gene Expression; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D020598:Proto-Oncogene Proteins c-myb; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis*
D011518:Proto-Oncogene Proteins; D020598:Proto-Oncogene Proteins c-myb; D016271:Proto-Oncogene Proteins c-myc